NRx Pharmaceuticals (NRXP)
(Delayed Data from NSDQ)
$3.25 USD
+0.30 (10.17%)
Updated Sep 29, 2025 04:00 PM ET
After-Market: $3.26 +0.01 (0.31%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
NRXP 3.25 +0.30(10.17%)
Will NRXP be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NRXP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NRXP
Here's Why NRx Pharmaceuticals (NRXP) Is a Great 'Buy the Bottom' Stock Now
NRx Pharmaceuticals to Post Q4 Earnings: How to Play the Stock?
NRXP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for January 6th
New Strong Buy Stocks for January 6th
Best Momentum Stocks to Buy for December 30th
Other News for NRXP
NRXP's Rating Maintained at 'Buy' by D. Boral Capital | NRXP Stock News
NRx Pharmaceuticals re-files abbreviated NDA for KETAFR
NRx Pharmaceuticals re-files abbreviated NDA for KETAFR
NRXP forms 20 Day Moving Average Support on September 26
NRX Pharmaceuticals Gains FDA Approval for KETAFREEā¢